Predictive Significance of CD276/B7-H3 Expression in Baseline Biopsies of Advanced Prostate Carcinoma

TL;DR

This study demonstrates that high CD276/B7-H3 expression in initial prostate biopsies correlates with metastatic disease, poorer prognosis, and could serve as a prognostic marker and therapeutic target in advanced prostate cancer.

Contribution

It is the first to link B7-H3 expression levels with clinical outcomes and metastatic status in prostate cancer at diagnosis.

Findings

Higher B7-H3 levels are associated with metastasis.

B7-H3 expression correlates with shorter survival.

B7-H3 may serve as a prognostic marker and therapeutic target.

Abstract

At the time of diagnosis, prostate cancer can appear deceptively mild or already display signs of widespread disease. Predicting long-term outcomes is often uncertain. This research focused on measuring CD276/B7-H3, an immune checkpoint protein linked to tumor development, in diagnostic tissue samples from 248 men. Participants included both those with cancer confined to the prostate and those with confirmed metastases. Analysis showed that patients with metastatic disease were more likely to exhibit increased B7-H3 levels. Strong expression of this marker was associated with shorter survival times and was observed alongside higher PSA concentrations and greater tumor aggressiveness based on Gleason grading. These trends remained consistent even when other prognostic factors were taken into account. The results suggest that assessing B7-H3 during the initial biopsy could help clinicians identify high-risk patients earlier. This marker may also represent a new target for treatment strategies in advanced prostate cancer.